Hunan Jiudian Pharmaceutical Co., Ltd. (Stock Code: 300705), founded in 2001, is a modern listed pharmaceutical company with a diversified presence across chemical drug preparations, active pharmaceutical ingredients (APIs), pharmaceutical excipients, traditional Chinese medicine (TCM), health foods, and rehabilitation & wellness products. In 2025, the company achieved operating revenue of RMB 3.11 billion, net profit of RMB 470 million, and tax payment of RMB 330 million.

Consolidating a solid foundation. In the field of topical preparations, the company has successfully launched nearly 10 products, with over 10 more under development or review, boasting a well-established product matrix, prominent star products, and significant developmental advantages. For oral preparations, the company holds over 180 product approvals, with more than 40 varieties passing generic drug consistency evaluation and 10 varieties selected for national centralized procurement, which will continue to unlock market potential. The company is also building competitive platforms for specialty APIs and high-end pharmaceutical excipients, with over 200 varieties registered and filed, and over 130 varieties converted to “A” status. The deep and extensive layout of its diversified product matrix and omnichannel sales system has solidified the foundation for the company’s steady growth.

Focusing on transdermal drug delivery. Through a synergistic approach combining in-house R&D and mergers & acquisitions (both primary and supplementary), the company has built a transdermal product portfolio that integrates chemical drugs and TCM in a complementary manner, cultivating multiple “golden” transdermal products that have received strong market response, with market shares firmly among the top in China. Over the next 3–5 years, more than 10 new transdermal products, including several Class 1.1 innovative drugs, will be launched sequentially, further strengthening the company’s leading position in this niche segment.

Accelerating innovative drug R&D. The company has brought together top domestic innovative drug R&D talents, established an Innovation Drug Research Institute, and leveraged the National Enterprise Technology Center, Postdoctoral Research Workstation, and several provincial-level innovation platforms to vigorously advance the R&D of innovative chemical drugs and TCM. The company has also recruited renowned overseas-trained Ph.D.s to lead the establishment of Jiudian Synno Innovation Drug Company, focusing on innovative drug R&D and technological collaboration. Currently, multiple innovative drug projects have entered the stages of manufacturing application or clinical trials, and research on novel targets is progressing steadily. In the future, through in-house R&D, collaboration, and M&A, the company will continue to refine its innovative drug pipeline and echelon, actively promote the global licensing of innovative drug rights, and enhance its international influence.